Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Det nationale australske HCV Point-of-Care-testprogram - minimalt datasæt

23. september 2026 opdateret af: Kirby Institute

Det nationale australske HCV Point-of-Care-testprogram: En observationel kohorteundersøgelse til at evaluere brugen af ​​finger-stick Point-of-care Hepatitis C-testning for at forbedre diagnosticering og behandling af HCV-infektion - minimalt datasæt

The National Australian HCV Point-of-Care Testing Program will establish an observational cohort to evaluate whether scale-up of finger-stick point-of-care HCV testing increases diagnosis and treatment for HCV infection. Participants will be recruited from settings providing services to people with a risk factor for the acquisition of HCV infection (including drug treatment clinics, needle and syringe programs, homelessness settings, mental health services, prisons, and mobile outreach). All participants who undergo HCV point-of-care testing at the study site will be included in the data collection. Participants will not receive treatment as a part of this study. Participants who are HCV RNA positive will be linked to standard of care.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

The advent of simple direct-acting antiviral hepatitis C (HCV) therapies with cure rates >95% is one of the greatest medical advances in decades, having led to a reversal in liver-related mortality. In Australia, treatment uptake has declined between 2016 (32,000 treated) and 2019/20 (2019: 11,500; 2020: 8,500).1 Progress towards HCV elimination has been impeded by COVID-19, affecting the delivery of national and state-based HCV strategies. Improving HCV treatment uptake to reduce disease burden is a key aim of global, national and state-based HCV strategies.2-4

Scale-up of HCV testing and treatment will be required to achieve elimination by 2030. Current diagnostic pathways require multiple visits to a practitioner reducing the proportion who receive a diagnosis. In Australia, 81% of people have had HCV antibody testing (indicates exposure), but only 47% have been HCV RNA tested (indicates active infection and the need for HCV treatment).5 Mathematical modelling suggests that HCV RNA testing needs to increase by at least 50% annually to achieve elimination in Australia by 2030.6

The Kirby Institute is an international leader in research evaluating the Xpert HCV assay (Grebely Lancet Gastro Hep 2017), having built a large network of Xpert platforms for HCV testing in needle and syringe programs, prisons, drug treatment clinics, tertiary hospitals, and Aboriginal Community Controlled Health Service. In Kirby-led research, point-of-care HCV testing interventions in needle and syringe programs and prisons have resulted in high HCV treatment uptake (70-90%). The Kirby Institute and Flinders University also have a strong track record of implementing point-of-care testing for STIs and COVID-19, providing an ideal foundation to scale-up Xpert HCV testing in Australia.

The Kirby Institute and Flinders University will establish the Australian National HCV Point-of-care Testing Program for the scale-up of point-of-care HCV RNA testing in services with high prevalence of HCV infection, including community health centres, drug treatment clinics, needle and syringe programs, and prisons. This program will include the development of standard operating procedures, logistics/deployment, initial set-up, an operator training program, and quality assurance and competency assessment program.

An observational cohort study will be established to evaluate HCV treatment uptake following scale-up of point-of-care HCV testing among people with a risk factor for acquisition of HCV infection or people attending a service caring for people with risk factors for the acquisition of HCV infection.

Participants will be recruited from settings that provide services to people with a risk factor for the acquisition of HCV infection. All participants who undergo point-of-care HCV testing at the study site will be included in the data collection. Participants will not receive treatment as a part of this study. Participants who are HCV RNA positive will be linked to standard of care for any other clinical assessments and treatment initiation.

Undersøgelsestype

Observationel

Tilmelding (Anslået)

80000

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • New South Wales
      • Sydney, New South Wales, Australien
        • Aktiv, ikke rekrutterende
        • Justice Health and Forensic Mental Health Network
    • Queensland
      • Aldershot, Queensland, Australien, 4650
      • Brisbane, Queensland, Australien, 4000
        • Rekruttering
        • QuIHN
        • Kontakt:
      • Cairns, Queensland, Australien
        • Rekruttering
        • Lotus Glen Correctional Centre
        • Kontakt:
          • Darren Russell
        • Ledende efterforsker:
          • Darren Russell
      • Coorparoo, Queensland, Australien, 4151
        • Afsluttet
        • Hepatitis Queensland
      • Ipswich, Queensland, Australien
        • Rekruttering
        • West Moreton Hospital and Health Service
        • Kontakt:
          • Blake Ponting
        • Ledende efterforsker:
          • Blake Ponting
      • Rathdowney, Queensland, Australien, 4287
      • Townsville, Queensland, Australien
        • Rekruttering
        • Townsville Correctional Centre
        • Kontakt:
          • John Morey
        • Ledende efterforsker:
          • John Morey
      • Woodford, Queensland, Australien
        • Rekruttering
        • Woodford Correctional Centre
        • Kontakt:
          • Rajendra Prakash
        • Ledende efterforsker:
          • Rajendra Prakash
    • South Australia
      • Hackney, South Australia, Australien, 5069
      • Marden, South Australia, Australien, 5070
        • Ikke rekrutterer endnu
        • South Australian Prison Health Service
        • Kontakt:
          • Tom Turnbull
        • Ledende efterforsker:
          • Tom Turnbull
      • Mount Gambier, South Australia, Australien, 5290
        • Rekruttering
        • Mount Gambier Priosn
        • Kontakt:
          • William Galloway
        • Ledende efterforsker:
          • William Galloway
    • Victoria
      • Fitzroy, Victoria, Australien, 3065
        • Aktiv, ikke rekrutterende
        • St Vincent's Correctional Health Services
      • Melbourne, Victoria, Australien, 3000
        • Rekruttering
        • Medically Supervised Injecting Room
        • Kontakt:
          • Nathan Stam
        • Ledende efterforsker:
          • Nathan Stam
      • Ravenhall, Victoria, Australien, 3023
        • Rekruttering
        • Dame Phyllis Frost Centre
        • Kontakt:
      • Ravenhall, Victoria, Australien, 3023
        • Rekruttering
        • Geo Healthcare - The Geo Group Australia Pty Ltd
        • Kontakt:
          • David Grace
        • Ledende efterforsker:
          • David Grace

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Sandsynlighedsprøve

Studiebefolkning

Participants will be recruited from settings that provide services to people with a risk factor for the acquisition of HCV infection, including drug treatment clinics, needle and syringe programs, prisons, mobile outreach services, community health services, mental health services, homelessness services, and other appropriate settings nationally. It is anticipated approximately 40,000 participants will be screened for HCV infection using point-of-care HCV testing.

Beskrivelse

Inclusion Criteria:

  • ≥ 18 years of age.
  • Received point-of-care HCV testing.

Exclusion Criteria:

  • Nil

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
People at risk of HCV acquisition

Clinic staff will offer HCV point-of-care testing to participants as they access services. Testing will be performed using point-of-care HCV RNA testing.

Participants will be offered finger-stick point-of-care testing for HCV

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
The proportion of HCV infected participants who initiate HCV treatment at 12 weeks
Tidsramme: 12 Weeks from enrolment

To evaluate the proportion of HCV infected (HCV RNA quantifiable) participants who initiate HCV treatment at 12 weeks following finger-stick point-of-care HCV RNA testing.

12 Weeks from enrolment

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
The proportion of participants who accept point-of-care testing
Tidsramme: 2 years from recruitment commencement

To evaluate the proportion of people who accept point-of-care testing among those offered testing.

2 years from recruitment commencement
The prevalence of HCV infection amongst study participants tested
Tidsramme: 2 years from recruitment commencement

To evaluate the prevalence of current HCV infection (HCV RNA quantifiable) among people tested.

2 years from recruitment commencement
To evaluate the time to HCV treatment uptake among HCV RNA positive participants
Tidsramme: 52 weeks

To evaluate the length of time participants take to initiate HCV treatment after diagnosis

52 weeks
To evaluate proportion of HCV RNA positive participants who initiate HCV treatment
Tidsramme: 52 weeks

To evaluate the proportion of HCV RNA positive participants who initiate HCV treatment at 12 months (52 weeks) following finger-stick point-of-care HCV RNA testing.

52 weeks
To evaluate the proportion of participants who complete HCV (DAA) treatment
Tidsramme: 52 weeks

To evaluate the proportion of participants who complete HCV direct-acting antiviral (DAA) treatment.

52 weeks
To evaluate the proportion of participants who achieve an SVR
Tidsramme: 12 weeks

To evaluate the proportion of participants who achieve an SVR (defined as HCV RNA below the lower limit of quantitation at post treatment week 12).

12 weeks
To evaluate the proportion of participants who are HCV RNA negative at 12 months
Tidsramme: 52 weeks

To evaluate the proportion of participants who are HCV RNA negative at 12 months (52 weeks) following finger-stick point-of-care HCV RNA testing.

52 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

23. januar 2023

Primær færdiggørelse (Anslået)

1. december 2029

Studieafslutning (Anslået)

1. december 2029

Datoer for studieregistrering

Først indsendt

12. december 2021

Først indsendt, der opfyldte QC-kriterier

9. februar 2022

Først opslået (Faktiske)

21. februar 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

28. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

23. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Andre undersøgelses-id-numre

  • VHCRP2104

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

IPD-planbeskrivelse

Request to share IPD will be considered by the protocol steering committee on individual basis

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .